SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC

Sponsor
Huazhong University of Science and Technology
Study ID
NCT06516445
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • SCRT — RADIATION
    5×5Gy，5Gy/d，QD，D1-D5
  • Camrelizumab — DRUG
    200mg, D1, ivgtt, Q3W, C1-4
  • Fluzoparib — DRUG
    100mg, BID, PO, Q3W, C1-4
  • CAPEOX — DRUG
    Capecitabine: 1000 mg/m2, BID, PO，D1-14, Q3W, C1-C4； Oxaliplatin: 130mg/m2, D1, ivgtt, 0-2h，Q3W，C1-4

Study Details

To explore the safety and efficacy of neoadjuvant therapy for locally advanced rectal cancer with short course radiotherapy followed by camrelizumab combined with fluzoparib and chemotherapy

Key Dates

Start date
Jun 28, 2023
Status verified
Jul 2024
Primary completion
Jun 28, 2025
Completion
Jun 28, 2026

Study Design

Enrollment
33 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: SCRT followed by camrelizumab combined with fluzoparib and chemotherapy

Primary Outcome Measure

Adverse events [ Time Frame: up to 36 months ]

Central Contacts

Related Studies